TPH1 Gene Polymorphism Analysis for IBS Treatment Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for predicting treatment response in irritable bowel syndrome (IBS) and Crohn's disease, particularly for determining the appropriate serotonin antagonist medication based on genetic polymorphisms.
Innovation Solution
A method involving nucleic acid detection assays to analyze specific polymorphisms in the tryptophan hydroxylase 1 (TPH1) gene, such as the -347 C/A polymorphism, to determine the suitability of serotonin antagonist medications like LX1031 for patients with IBS-D and Crohn's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If nucleic acid detection assays are used to analyze TPH1 gene polymorphisms, then treatment prediction accuracy is improved, but device complexity and cost increase
Solution Approach 1:
The patent extracts and analyzes specific polymorphic sites (such as -347 C/A) from the TPH1 gene promoter region using targeted nucleic acid detection assays. By focusing only on the critical genetic variants associated with treatment response rather than sequencing the entire gene, the method achieves high prediction accuracy while reducing assay complexity and cost.
2Reliability
If genetic analysis is performed to identify suitable patients for serotonin antagonist therapy, then treatment effectiveness is improved, but time and resource consumption increase
Solution Approach 1:
The patent performs preliminary genetic analysis using PCR-based detection of specific TPH1 polymorphisms before initiating serotonin antagonist therapy. By pre-identifying patients with favorable genetic profiles (such as those with specific -347 C/A genotypes) who are more likely to respond to treatment, the method ensures treatment effectiveness while minimizing the time required for genetic testing compared to broader genomic approaches.
Data Source
Figure 1A~1B
Figure 1C~1E
Figure 2
AI summary
The present invention provides compositions and methods for characterizing irritable bowel syndrome. In particular, the present invention provides compositions and methods for determining polymorphisms associated with IBS-D and Crohn's disease. The present invention further provides compositions and methods for determining a treatment course of action in subjects with IBS-D and Crohn's disease.